Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Identifying Ocular and Systemic Biomarkers for Response to Aflibercept in Asian Patients With Centre Involving Diabetic Macular Edema: A Prospective Interventional Trial

Trial Profile

Identifying Ocular and Systemic Biomarkers for Response to Aflibercept in Asian Patients With Centre Involving Diabetic Macular Edema: A Prospective Interventional Trial

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Aflibercept (Primary) ; Dexamethasone
  • Indications Diabetic macular oedema
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 14 Jul 2017 Planned initiation date changed from 1 Jul 2017 to 1 Aug 2017.
    • 27 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top